Get the Stockscreener App
59.24
0.25%
-0.15
After Hours:
59.25
0.010
+0.02%
Monopar Therapeutics Inc stock is traded at $59.24, with a volume of 329.30K.
It is down -0.25% in the last 24 hours and down -8.90% over the past month.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
See More
Previous Close:
$59.39
Open:
$59.03
24h Volume:
329.30K
Relative Volume:
1.26
Market Cap:
$395.88M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-17.23
EPS:
-3.4389
Net Cash Flow:
$-10.83M
1W Performance:
+4.15%
1M Performance:
-8.90%
6M Performance:
+65.01%
1Y Performance:
+17.26%
1-Day Range:
$57.65
$61.30
1-Week Range:
$54.90
$61.30
52-Week Range:
$26.05
$105.00
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Name
Monopar Therapeutics Inc
Sector
Industry
Phone
(847) 388-0349
Address
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
59.24 | 396.88M | 0 | -19.44M | -10.83M | -3.4389 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | Morgan Stanley | Overweight |
| Nov-14-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Nov-10-25 | Initiated | Leerink Partners | Outperform |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-09-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Aug-26-25 | Resumed | H.C. Wainwright | Buy |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-23-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-19-25 | Resumed | Piper Sandler | Overweight |
| Jan-10-25 | Initiated | Piper Sandler | Overweight |
| Oct-11-24 | Initiated | Rodman & Renshaw | Buy |
| Jan-28-21 | Initiated | ROTH Capital | Buy |
View All
Monopar Therapeutics Inc Stock (MNPR) Latest News
Institutional investors in Monopar Therapeutics Inc. (NASDAQ:MNPR) see US$66m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Stocks showing improved relative strength: Monopar Therapeutics - MSN
The Technical Signals Behind (MNPR) That Institutions Follow - Stock Traders Daily
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Short Interest in Monopar Therapeutics Inc. (NASDAQ:MNPR) Rises By 21.1% - MarketBeat
Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Monopar Therapeutics’ (MNPR) Buy Rating Reaffirmed at BTIG Research - Defense World
MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease - TipRanks
BTIG Reiterates Buy Rating on Monopar Therapeutics (MNPR) | MNPR Stock News - GuruFocus
BTIG Research Reaffirms "Buy" Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Bull Bear: Why is Monopar Therapeutics Inc stock going down2025 Dividend Review & Advanced Technical Analysis Signals - baoquankhu1.vn
Monopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at Chardan Capital - Defense World
Chardan Capital Reaffirms Buy Rating on MNPR with $100 Price Tar - GuruFocus
Chardan Capital Reaffirms Buy Rating for Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Precision Trading with Monopar Therapeutics Inc. (MNPR) Risk Zones - Stock Traders Daily
Breakout Move: Will Monopar Therapeutics Inc outperform tech stocksStop Loss & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Market Leaders: Will Monopar Therapeutics Inc outperform tech stocksMarket Rally & Growth Focused Entry Reports - baoquankhu1.vn
Janux Therapeutics Inc (JANX) Gets a Buy from JonesTrading - The Globe and Mail
JonesTrading Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $130 - 富途牛牛
Monopar Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Monopar Therapeutics: Tiny Cancer-Drug Stock Caught Between Speculation And Survival - AD HOC NEWS
Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 28.3% in December - MarketBeat
Fundamentals Check: Why is Monopar Therapeutics Inc stock going downJuly 2025 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn
Technical Reactions to MNPR Trends in Macro Strategies - Stock Traders Daily
Price Action: Is Monopar Therapeutics Inc impacted by rising rates2025 Risk Factors & Short-Term High Return Ideas - baoquankhu1.vn
History Review: Is CO2 Energy Transition Corp a stock for growth or value investors2025 Geopolitical Influence & High Win Rate Trade Tips - baoquankhu1.vn
BTIG Reiterates Buy Rating for MNPR with $104 Target Price | MNP - GuruFocus
Monopar Therapeutics' (MNPR) "Buy" Rating Reiterated at BTIG Research - MarketBeat
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts - TipRanks
BTIG reiterates Buy rating on Monopar Therapeutics stock ahead of NDA submission - Investing.com Canada
Momentum Shift: How strong is Monopar Therapeutics Inc stock balance sheetMarket Volume Summary & Technical Entry and Exit Alerts - Bộ Nội Vụ
Aug Closing: Is Monopar Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Earnings Recap & Safe Entry Momentum Stock Tips - Bộ Nội Vụ
Sentiment Recap: Is Monopar Therapeutics Inc. stock a safe haven assetInflation Watch & Reliable Intraday Trade Alerts - Bộ Nội Vụ
CEO Moves: How cyclical is Monopar Therapeutics Inc. (1IY0) stock compared to rivals2025 Institutional Moves & Daily Market Momentum Tracking - Bộ Nội Vụ
How dovish Fed policy supports Monopar Therapeutics Inc. (1IY0) stock2025 Market WrapUp & Weekly Watchlist for Hot Stocks - Улправда
Monopar Therapeutics (NASDAQ:MNPR) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Monopar Therapeutics (NASDAQ:MNPR) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Monopar Therapeutics initiated with an Overweight at Morgan Stanley - TipRanks
Morgan Stanley Initiates Coverage on Monopar Therapeutics (MNPR) - GuruFocus
Morgan Stanley initiates Monopar Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives Average Rating of “Buy” from Brokerages - Defense World
Why Monopar Therapeutics Inc. stock appeals to analystsPrice Action & Daily Growth Stock Tips - ulpravda.ru
Can Monopar Therapeutics Inc. stock maintain operating marginsTrade Exit Report & Free Low Drawdown Momentum Trade Ideas - ulpravda.ru
How risky is Monopar Therapeutics Inc. stock nowWeekly Investment Recap & Free Community Consensus Stock Picks - Улправда
symbol__ Stock Quote Price and Forecast - CNN
Will Monopar Therapeutics Inc. stock return to pre crisis levelsJuly 2025 News Drivers & Fast Moving Stock Watchlists - Улправда
Can Monopar Therapeutics Inc. stock hit record highs again2025 Macro Impact & Weekly Return Optimization Alerts - Улправда
Published on: 2026-01-09 02:26:30 - ulpravda.ru
Published on: 2026-01-09 02:04:15 - Улправда
Will Monopar Therapeutics Inc. stock keep outperforming rivalsEntry Point & Low Risk Investment Opportunities - Улправда
Will Monopar Therapeutics Inc. stock gain from strong economyWeekly Trade Analysis & Capital Efficient Trade Techniques - ulpravda.ru
Monopar Therapeutics Inc Stock (MNPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):